NEW OPPORTUNITIES IN TREATMENT OF CHRONIC HEART FAILURE WITH NORMAL EJECTION FRACTION

Aim. To evaluate aim worthiness and efficacy of the application of angiotensin type II receptor blockers (ARB) and calcium channel antagonists (CCA) in patients with early stages of chronic heart failure with normal ejection fraction (CHF-NEF) developed on the background of arterial hypertension and arterial hypertension with ischemic heart disease. Material and methods. Totally 67 patients included with CHF-NEF (EF>50%), of I-IIA stage, I-III functional class (FC), developed over arterial hypertension and arterial hypertension with ischemic heart disease. Depending on the specifics of treatment patients were selected into 2 groups: main (n=37) group— taking ARBs (valsartan, average dosage 130,8±38,8mg/ day) and CCA (S(-) amlodipine, average dosage 3,2±1,1 mg/day) with the standard therapy of CHF, and control group (n=30) taking only standard treatment. Investigation in all patients took place before the beginning of treatment and in 12 weeks and included anamnesis, examination, electrocardiography and Holter monitoring, echocardiography, 6-minute test (SMT), evaluation of CHF severity by the score of clinical condition (SCC), evaluation of life quality with Minnesota Questionnaire for Heart failure. Results. Intergroup analysis showed that the improvement of clinical condition by the SCC in the main group was -50,0 [-50,0; -31,0]%, in control group — -33,3 [-33,3; 0,0]% (р<0,05), SMT exercise tolerance — 11,6±8,4 and 6,6±10,6% (р<0,05), life quality -26,0 [-44,0; 0,0] and -26,8 [-33,3; -18,2]% (р>0,05), respectively. Among echocardiographic parameters only decrease of interventricular septum thickness was marked in both groups — -4,0±1,2 and -2,9±1,5%, resp., (р<0,05). Conclusion. Usage of ARB valsartan and CCA (S-) amlodipine in patients with earlier stages of CHF-NEF leads to more serious regression of myocardial hypertrophy of the left ventricle, the decrease of clinical symptomatic severity, improvement of exercise tolerance.

chronic heart failure with normal ejection fraction, calcium channel antagonists, angiotensin II receptor blockers

1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93(9):1137-46.

2. Headenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123(8): 933-44.

3. Echeverria HH, Bilsker MS, Myerburg RJ, et al. Congestive heart failure: Echocardiography insights. Am J Med 1983; 75(5): 750-55.

4. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New Engl J Med 2006; 355(3): 251-59.

5. Smiseth OA, Tendera M. Diastolic heart failure. Springer-Verlag London Limitted 2008; 349 p.

6. Mareev VYu. the Contribution of a violation of diastole in the formation and progression of cardiovascular continuum Heart. Educational application: Heart failure with preserved systolic left ventricular function — the epidemic of the XXI century, 2010; 2: 1-5. Russian (Мареев В. Ю. Вклад нарушения диастолы в формирование и прогрессирование сердечно-сосудистого континуума Сердце. Образовательное приложение: Сердечная недостаточность с сохраненной систолической функцией левого желудочка — эпидемия XXI века 2010; 2: 1-5).

7. Van Heerebeek L, Borbely A, Niessen HWM et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006; 113(16): 1966-73.

8. National guidelines SSHF, RSC and RNMOT for the diagnosis and treatment of CHF (fourth revision). Heart failure 2013; 14(7): 379-472. Russian (Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность 2013; 14(7): 379-472).

9. Tereschenko SN. Diastolic heart failure: soluble Lee difficulties of diagnosis and treatment? Therapeutic archive 2009; 81(11): 73-6. Russian (Терещенко С. Н. Диастолическая сердечная недостаточность: разреши¬мы ли трудности диагностики и лечения? Терапевтический архив 2009; 81(11): 73-6).

10. Ha J-W, Oh JK. Therapeutic strategies for diastolic dysfunction: a clinical perspective. Cardiovascular Ultrasound 2009; 17(3): 86-95.

11. Guyatt GH, Thompson PL, Berman LB, et al. How should we measure function in patients with chronic heart and lung disease? J Chron Dis 1985; 38(6): 517-24.

12. Mentz RJ, Kelly JP, Von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. Journal of the American College of Cardiology 2014; 64(21): 2281-93.

13. McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure 2012; 14(8): 803-69.

14. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Progress in Cardiovascular Diseases 2005; 47(5): 320-32.

15. Epidemiology of chronic heart failure in the Russian Federation. Chronic heart failure. Moscow: GEOTAR-Media 2010: 7-77. Russian (Эпидемиология хронической сердечной недостаточности в Российской Федерации. Хроническая сердечная недостаточность. М.: ГЭОТАР-Медиа 2010: 7-77).